Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES

To watch the video series component of this episode, click here.

Podcasts

Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, interview Scott Kahan, MD, MPH who serves on the committee that creates the ADA Standards of Care in Diabetes, to discuss the latest updates in weight management guidelines.

Updates in the Standards of Care in Diabetes in 2023 - Obesity and Weight Management

In this MEDcast® episode, Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES, interview Sumita Singh to discuss her family’s journey as they navigated the challenges of their daughter’s T1D diagnosis and decided to enroll her in a clinical trial for a T1D treatment.

Embracing Research and Finding Support to Manage Type 1 Diabetes

On March 2, the diabetes community took a major step forward with the Centers for Medicare and Medicaid Services (CMS) announcement of expansion of their continuous glucose monitoring (CGM) access coverage for people with diabetes.

The policy update, which expanded coverage to include insulin users with diabetes and traditional Medicare coverage and people with diabetes not using with a history of problematic hypoglycemia, is scheduled to go into effect on April 16, 2023.

Less than a week later, the community welcomed more transformative news in the world of diabetes technology with Abbott’s announcement of a new clearance from the US Food and Drug Administration for their FreeStyle Libre sensors.

 Announced by Abbott on March 6, the US Food and Drug Administration’s clearance of the FreeStyle Libre 2 and FreeStyle Libre 3 allows for integration with automated insulin delivery systems opens the door for a seismic shift in the realm of patient choice in diabetes technology. In their announcement, Abbott noted the rollout of modified sensors was expected later this year and the company also called attention to several ongoing partnerships with leading pump manufacturers, both within and outside of the US.

In this special edition in-studio version of 

Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives

hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and cooridnator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner at R&B Medical Group, offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes, providers, and diabetes care and education specialists. Later in the episode, hosts take a deep dive into the announcement from Abbott and what this new clearance means for patients.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

 is available in an audio-only format on 

Glucose Monitor - policy article. CMS.gov Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52464&ver=49&contractorName=all&sortBy=updated&bc=13. Accessed March 17, 2023.

Campbell P. Freestyle Libre sensors cleared for integration with automated insulin delivery systems. HCP Live. https://www.hcplive.com/view/freestyle-libre-cleared-for-integration-with-automated-insulin-delivery-systems. Published March 6, 2023. Accessed March 17, 2023.

In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.

Diabetes Dialogue: CMS Expansion Ushers in New Age of CGM Access

Hosts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Emily Sims, MD, to discuss the latest clinical evidence on teplizumab and other emerging treatments that can delay the onset of type 1 diabetes.

Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES

Articles